{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:35:58Z","timestamp":1792197358117,"version":"4.4.0"},"reference-count":47,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2002,12,1]]},"abstract":"<jats:p>Reoviruses infect cells that manifest an activated Ras-signaling pathway, and have been shown to effectively destroy many different types of neoplastic cells, including those derived from brain, breast, colon, ovaries, and prostate. In this study, we investigated the reovirus as a potential therapeutic agent against lymphoid malignancies. A total of 9 lymphoid cell lines and 27 primary human lymphoid malignancies, as well as normal lymphocytes and hematopoietic stem\/progenitor cells, were tested for susceptibility to reovirus infection. For in vitro studies, the cells were challenged with reovirus (serotype 3 Dearing), and viral infection was assessed by cytopathic effects, viability, viral protein synthesis, and progeny virus production. We present evidence of efficient reovirus infection and cell lysis in the diffuse large B-cell lymphoma cell lines and Burkitt lymphoma cell lines Raji and CA46 but not Daudi, Ramos, or ST486. Moreover, when Raji and Daudi cell lines were grown subcutaneously in severe combined immunodeficient\/nonobese diabetic (SCID\/NOD) mice and subsequently injected with reovirus intratumorally or intravenously, significant regression was observed in the Raji-induced, but not the Daudi-induced, tumors, which is consistent with the in vitro results. Susceptibility to reovirus infection was also detected in 21 of the 27 primary lymphoid neoplasias tested but not in the normal lymphocytes or hematopoietic stem\/progenitor cells. Our results suggest that reovirus may be an effective agent against several types of human lymphoid malignancies.<\/jats:p>","DOI":"10.1182\/blood-2002-02-0503","type":"journal-article","created":{"date-parts":[[2002,11,14]],"date-time":"2002-11-14T17:42:59Z","timestamp":1037295779000},"page":"4146-4153","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":84,"title":["Reovirus therapy of lymphoid malignancies"],"prefix":"10.1182","volume":"100","author":[{"given":"Tommy","family":"Alain","sequence":"first","affiliation":[{"name":"From the Calgary Laboratory Services, AB, Canada; the Cancer Biology Research Group, the Department of Pathology, the Department of Microbiology and Infectious Diseases, and the Department of Medical Biochemistry, University of Calgary, AB, Canada; and the Department of Medicine, University of Alberta, and the Canadian Blood Services, Edmonton, AB, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Hirasawa","sequence":"additional","affiliation":[{"name":"From the Calgary Laboratory Services, AB, Canada; the Cancer Biology Research Group, the Department of Pathology, the Department of Microbiology and Infectious Diseases, and the Department of Medical Biochemistry, University of Calgary, AB, Canada; and the Department of Medicine, University of Alberta, and the Canadian Blood Services, Edmonton, AB, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly J.","family":"Pon","sequence":"additional","affiliation":[{"name":"From the Calgary Laboratory Services, AB, Canada; the Cancer Biology Research Group, the Department of Pathology, the Department of Microbiology and Infectious Diseases, and the Department of Medical Biochemistry, University of Calgary, AB, Canada; and the Department of Medicine, University of Alberta, and the Canadian Blood Services, Edmonton, AB, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra G.","family":"Nishikawa","sequence":"additional","affiliation":[{"name":"From the Calgary Laboratory Services, AB, Canada; the Cancer Biology Research Group, the Department of Pathology, the Department of Microbiology and Infectious Diseases, and the Department of Medical Biochemistry, University of Calgary, AB, Canada; and the Department of Medicine, University of Alberta, and the Canadian Blood Services, Edmonton, AB, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan J.","family":"Urbanski","sequence":"additional","affiliation":[{"name":"From the Calgary Laboratory Services, AB, Canada; the Cancer Biology Research Group, the Department of Pathology, the Department of Microbiology and Infectious Diseases, and the Department of Medical Biochemistry, University of Calgary, AB, Canada; and the Department of Medicine, University of Alberta, and the Canadian Blood Services, Edmonton, AB, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonna","family":"Auer","sequence":"additional","affiliation":[{"name":"From the Calgary Laboratory Services, AB, Canada; the Cancer Biology Research Group, the Department of Pathology, the Department of Microbiology and Infectious Diseases, and the Department of Medical Biochemistry, University of Calgary, AB, Canada; and the Department of Medicine, University of Alberta, and the Canadian Blood Services, Edmonton, AB, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Luider","sequence":"additional","affiliation":[{"name":"From the Calgary Laboratory Services, AB, Canada; the Cancer Biology Research Group, the Department of Pathology, the Department of Microbiology and Infectious Diseases, and the Department of Medical Biochemistry, University of Calgary, AB, Canada; and the Department of Medicine, University of Alberta, and the Canadian Blood Services, Edmonton, AB, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Martin","sequence":"additional","affiliation":[{"name":"From the Calgary Laboratory Services, AB, Canada; the Cancer Biology Research Group, the Department of Pathology, the Department of Microbiology and Infectious Diseases, and the Department of Medical Biochemistry, University of Calgary, AB, Canada; and the Department of Medicine, University of Alberta, and the Canadian Blood Services, Edmonton, AB, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randal N.","family":"Johnston","sequence":"additional","affiliation":[{"name":"From the Calgary Laboratory Services, AB, Canada; the Cancer Biology Research Group, the Department of Pathology, the Department of Microbiology and Infectious Diseases, and the Department of Medical Biochemistry, University of Calgary, AB, Canada; and the Department of Medicine, University of Alberta, and the Canadian Blood Services, Edmonton, AB, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Janowska-Wieczorek","sequence":"additional","affiliation":[{"name":"From the Calgary Laboratory Services, AB, Canada; the Cancer Biology Research Group, the Department of Pathology, the Department of Microbiology and Infectious Diseases, and the Department of Medical Biochemistry, University of Calgary, AB, Canada; and the Department of Medicine, University of Alberta, and the Canadian Blood Services, Edmonton, AB, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick W. K.","family":"Lee","sequence":"additional","affiliation":[{"name":"From the Calgary Laboratory Services, AB, Canada; the Cancer Biology Research Group, the Department of Pathology, the Department of Microbiology and Infectious Diseases, and the Department of Medical Biochemistry, University of Calgary, AB, Canada; and the Department of Medicine, University of Alberta, and the Canadian Blood Services, Edmonton, AB, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna E.","family":"Kossakowska","sequence":"additional","affiliation":[{"name":"From the Calgary Laboratory Services, AB, Canada; the Cancer Biology Research Group, the Department of Pathology, the Department of Microbiology and Infectious Diseases, and the Department of Medical Biochemistry, University of Calgary, AB, Canada; and the Department of Medicine, University of Alberta, and the Canadian Blood Services, Edmonton, AB, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111610403512100_B1","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/jnci\/93.12.903","article-title":"Reovirus as an oncolytic agent against experimental human malignant gliomas.","volume":"93","author":"Wilcox","year":"2001","journal-title":"J Natl Cancer Inst."},{"key":"2019111610403512100_B2","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1089\/10430340252837233","article-title":"Reovirus Oncolysis of Human Breast Cancer.","volume":"13","author":"Norman","year":"2002","journal-title":"Hum Gene Ther."},{"key":"2019111610403512100_B3","first-page":"1696","article-title":"Oncolytic reovirus against ovarian and colon cancer.","volume":"62","author":"Hirasawa","year":"2002","journal-title":"Cancer Res."},{"key":"2019111610403512100_B4","first-page":"2248","article-title":"Reovirus induces apoptosis in breast and prostate cell lines and activates Nf-kB in the nucleus: implications for a prognostic factor in successful reovirus therapy [abstract].","volume":"42","author":"Thirukkumaran","year":"2001","journal-title":"Proc Am Assoc Cancer Res."},{"key":"2019111610403512100_B5","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1006\/viro.1993.1602","article-title":"Evidence that the epidermal growth factor receptor on host cells confers reovirus infection efficiency.","volume":"197","author":"Strong","year":"1993","journal-title":"Virology."},{"key":"2019111610403512100_B6","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1128\/JVI.70.1.612-616.1996","article-title":"The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection.","volume":"70","author":"Strong","year":"1996","journal-title":"J Virol."},{"key":"2019111610403512100_B7","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1093\/emboj\/17.12.3351","article-title":"The molecular basis of viral onoclysis: usurpation of the Ras-signaling pathway by reovirus.","volume":"17","author":"Strong","year":"1998","journal-title":"EMBO J."},{"key":"2019111610403512100_B8","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1126\/science.282.5392.1332","article-title":"Reovirus therapy of tumors with activated Ras pathway.","volume":"282","author":"Coffey","year":"1998","journal-title":"Science."},{"key":"2019111610403512100_B9","first-page":"1597","article-title":"Reoviruses.","volume-title":"Virology.","author":"Tyler","year":"1996"},{"key":"2019111610403512100_B10","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.","volume":"84","author":"Harris","year":"1994","journal-title":"Blood."},{"key":"2019111610403512100_B11","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2","article-title":"summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project.","volume":"49","author":"National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas","year":"1982","journal-title":"Cancer."},{"key":"2019111610403512100_B12","first-page":"443","article-title":"Non-Hodgkin's lymphoma: biologic classification, diagnosis and treatment [in Spanish].","volume":"134","author":"Jimenez-Zepeda","year":"1998","journal-title":"Gac Med Mex."},{"key":"2019111610403512100_B13","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project.","volume":"329","year":"1993","journal-title":"N Engl J Med."},{"key":"2019111610403512100_B14","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/bjc.1995.406","article-title":"Treatment and survival of lymphoid malignancy in the north-west of England: a population-based study.","volume":"72","author":"Youngson","year":"1995","journal-title":"Br J Cancer."},{"key":"2019111610403512100_B15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/annonc\/5.suppl_2.S5","article-title":"Modern treatment of malignant lymphomas: a multidisciplinary approach? The Kaplan Memorial Lecture.","volume":"2","author":"Bonadonna","year":"1994","journal-title":"Ann Oncol."},{"key":"2019111610403512100_B16","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1200\/JCO.2000.18.21.3707","article-title":"Molecular biology of Burkitt's lymphoma.","volume":"18","author":"Hecht","year":"2000","journal-title":"J Clin Oncol."},{"key":"2019111610403512100_B17","first-page":"31","article-title":"Molecular biology of lymphomas.","volume":"5","author":"Croce","year":"1993","journal-title":"Semin Oncol."},{"key":"2019111610403512100_B18","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/beha.2001.0150","article-title":"Overview: cytogenetic analysis in haematology.","volume":"14","author":"Bain","year":"2001","journal-title":"Best Pract Res Clin Haematol."},{"key":"2019111610403512100_B19","first-page":"5","article-title":"Cytogenetic abnormalities in chronic lymphocytic leukemia.","volume":"42","author":"Karnolsky","year":"2000","journal-title":"Folia Med (Plovdiv)."},{"key":"2019111610403512100_B20","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1182\/blood.V81.1.166.166","article-title":"Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma.","volume":"81","author":"Ballerini","year":"1993","journal-title":"Blood."},{"key":"2019111610403512100_B21","first-page":"844","article-title":"Mutation of the ras genes is a rare genetic event in the histologic transformation of follicular lymphoma.","volume":"10","author":"Clark","year":"1996","journal-title":"Leukemia."},{"key":"2019111610403512100_B22","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/(SICI)1097-0215(19970502)71:3<364::AID-IJC10>3.0.CO;2-G","article-title":"A one-step DGGE scanning method for the detection of mutations in the K-, N-, and H-ras oncogenes: mutations at codons 12, 13 and 61 are rare in B-cell non-Hodgkin's lymphoma.","volume":"71","author":"Nedergaard","year":"1997","journal-title":"Int J Cancer."},{"key":"2019111610403512100_B23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/carcin\/11.1.1","article-title":"Neoplastic development in B-lymphocytes.","volume":"11","author":"Potter","year":"1990","journal-title":"Carcinogenesis."},{"key":"2019111610403512100_B24","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1006\/viro.1997.8901","article-title":"Activation of a ras-MAPK-dependent pathway by Epstein-Barr virus latent membrane protein 1 is essential for cellular transformation.","volume":"240","author":"Roberts","year":"1998","journal-title":"Virology."},{"key":"2019111610403512100_B25","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3109\/10428190009058499","article-title":"CD40 ligand in CLL pathogenesis and therapy.","volume":"37","author":"Schattner","year":"2000","journal-title":"Leuk Lymphoma."},{"key":"2019111610403512100_B26","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.4049\/jimmunol.157.7.2844","article-title":"Activation of the Ras-signaling pathway by the CD40 receptor.","volume":"157","author":"Gulbins","year":"1996","journal-title":"J Immunol."},{"key":"2019111610403512100_B27","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/35085588","article-title":"Hympermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas.","volume":"412","author":"Pasqualucci","year":"2001","journal-title":"Nature."},{"key":"2019111610403512100_B28","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1182\/blood.V69.5.1307.1307","article-title":"The presence of clonogenic cells in high-grade malignant lymphoma: a prognostic factor.","volume":"69","author":"Tweeddale","year":"1987","journal-title":"Blood."},{"key":"2019111610403512100_B29","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1182\/blood.V93.10.3379.410k09_3379_3390","article-title":"Growth factors and cytokines upregulate gelatinase expression in bone marrow CD34+ cells and their transmigration through reconstituted basement membrane.","volume":"93","author":"Janowska-Wieczorek","year":"1999","journal-title":"Blood."},{"key":"2019111610403512100_B30","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/0042-6822(69)90017-8","article-title":"Polypeptide components of virions, top component and cores of reovirus type 3.","volume":"39","author":"Smith","year":"1969","journal-title":"Virology."},{"key":"2019111610403512100_B31","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/0042-6822(81)90533-X","article-title":"Characterization of anti-reovirus immunoglobulins secreted by cloned hybridoma cell lines.","volume":"108","author":"Lee","year":"1981","journal-title":"Virology."},{"key":"2019111610403512100_B32","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/227680a0","article-title":"Cleavage of structural proteins during the assembly of the head of bacteriophage T4.","volume":"227","author":"Laemmli","year":"1970","journal-title":"Nature."},{"key":"2019111610403512100_B33","volume-title":"Pathology and Genetics of Tumours of Haematopoietic and Lymphoid tissues. World Health Organization Classification of Tumours.","author":"Jaffe","year":"2001"},{"key":"2019111610403512100_B34","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S1040-8428(00)00069-X","article-title":"Treatment of B-cell non-Hodgkin's lymphoma with anti CD20 monoclonal antibody Rituximab.","volume":"37","author":"Sacchi","year":"2001","journal-title":"Crit Rev Oncol Hematol."},{"key":"2019111610403512100_B35","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.","volume":"90","author":"Malhoney","year":"1997","journal-title":"Blood."},{"key":"2019111610403512100_B36","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJM199308123290703","article-title":"Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody.","volume":"329","author":"Kaminski","year":"1993","journal-title":"N Engl J Med."},{"key":"2019111610403512100_B37","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1182\/blood.V65.6.1349.bloodjournal6561349","article-title":"A clinical trial of anti-idiotype therapy for B-cell malignancy.","volume":"65","author":"Meeker","year":"1985","journal-title":"Blood."},{"key":"2019111610403512100_B38","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1182\/blood.V89.9.3129","article-title":"Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma: long-term results of a clinical trial.","volume":"89","author":"Hsu","year":"1997","journal-title":"Blood."},{"key":"2019111610403512100_B39","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/sj.leu.2402208","article-title":"T cell activation following infection of primary follicle center lymphoma B cells with adenovirus encoding CD154.","volume":"15","author":"Cantwell","year":"2001","journal-title":"Leukemia."},{"key":"2019111610403512100_B40","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1182\/blood.V97.12.3746","article-title":"Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice.","volume":"97","author":"Grote","year":"2001","journal-title":"Blood."},{"key":"2019111610403512100_B41","first-page":"549","article-title":"High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity.","volume":"15","author":"van Besien","year":"1995","journal-title":"Bone Marrow Transplant."},{"key":"2019111610403512100_B42","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0936-6555(05)80813-1","article-title":"Combined chemotherapy and radiotherapy in diffuse large cell immunoblastic lymphoma: a phase II study of CHOP\/bleomycin\/methotrexate alternating with ifosfamide\/methotrexate\/etoposide.","volume":"7","author":"Rodriguez","year":"1995","journal-title":"Clin Oncol (R Coll Radiol)."},{"key":"2019111610403512100_B43","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/35087061","article-title":"Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1.","volume":"3","author":"Farassati","year":"2001","journal-title":"Nat Cell Biol."},{"key":"2019111610403512100_B44","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/BF01534703","article-title":"Chromosomal localization of three human ras genes by in situ molecular hybridization.","volume":"11","author":"Popescu","year":"1985","journal-title":"Somat Cell Mol Genet."},{"key":"2019111610403512100_B45","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/310784a0","article-title":"Localization of insulin-like growth factor genes to human chromosomes 11 and 12.","volume":"310","author":"Tricoli","year":"1984","journal-title":"Nature."},{"key":"2019111610403512100_B46","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.4049\/jimmunol.162.5.2555","article-title":"The EBV transforming protein, latent membrane protein 1, mimics and cooperates with CD40 signaling in B lymphocytes.","volume":"162","author":"Busch","year":"1999","journal-title":"J Immunol."},{"key":"2019111610403512100_B47","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1053\/beha.1999.0068","article-title":"Haematological associations of Epstein-Barr virus infection.","volume":"13","author":"Okano","year":"2000","journal-title":"Best Pract Res Clin Haematol."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/100\/12\/4146\/1252457\/h82302004146.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/100\/12\/4146\/1252457\/h82302004146.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T19:38:06Z","timestamp":1682365086000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/100\/12\/4146\/88302\/Reovirus-therapy-of-lymphoid-malignancies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,12,1]]},"references-count":47,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2002,12,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2002-02-0503","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2002,12,1]]}}}